Published in Clin Sci (Lond) on May 01, 1985
Reversible inhibition of leucocyte sodium pumps by a circulating serum factor in essential hypertension. Br Med J (Clin Res Ed) (1986) 0.94
Effects of serum, lithium, ethacrynic acid, and low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes. Br J Clin Pharmacol (1987) 0.85
Linearity of metoclopramide kinetics at doses of 5-20 mg. Br J Clin Pharmacol (1988) 0.80
Reversible inhibition of leucocyte sodium pumps by a serum factor in essential hypertension. Br Med J (Clin Res Ed) (1986) 0.75
Reversible inhibition of leucocyte sodium pumps by circulating serum factor in essential hypertension. Br Med J (Clin Res Ed) (1986) 0.75
Erythrocyte concentrations and transmembrane fluxes of sodium and potassium in essential hypertension: role of intrinsic and environmental factors. Cardiovasc Drugs Ther (1990) 0.75
Diuretics and cation transport in hypertensive blacks. Cardiovasc Drugs Ther (1990) 0.75
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet (1999) 4.96
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Influence of hospital and clinician workload on survival from colorectal cancer: cohort study. BMJ (1999) 2.98
Wernicke's encephalopathy: a more common disease than realised. A neuropathological study of 51 cases. J Neurol Neurosurg Psychiatry (1979) 2.73
Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med (2001) 2.68
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet (2003) 2.47
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol (2001) 2.33
Medication errors, worse than a crime. Lancet (2000) 2.24
A prescription for better prescribing. Br J Clin Pharmacol (2006) 2.24
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
The incidence of Wernicke's encephalopathy in Australia--a neuropathological study of 131 cases. J Neurol Neurosurg Psychiatry (1983) 2.07
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
New deal for old hearts. BMJ (1991) 1.90
Rare diseases and orphan drugs. Br J Clin Pharmacol (2006) 1.83
Misuse of temazepam. BMJ (1991) 1.82
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
A 'same day' direct-access chest pain clinic: improved management and reduced hospitalization. QJM (1998) 1.77
Balanced prescribing. Br J Clin Pharmacol (2006) 1.74
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Pernicious anaemia in Indian immigrants in the London area. Br J Haematol (1970) 1.56
Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J (2013) 1.55
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart (2006) 1.55
Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin Radiol (2003) 1.52
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J (2002) 1.52
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet (2002) 1.46
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
Rational prescribing, appropriate prescribing. Br J Clin Pharmacol (2004) 1.43
The effect of the general practice registrar year on perceived skills in palliative care in the West Midlands. Med Educ (2000) 1.42
Prescribing statins. Br J Clin Pharmacol (2005) 1.42
Dural arteriovenous fistula in association with heterotopic brain nodule in the transverse sinus. AJNR Am J Neuroradiol (1998) 1.40
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40
Hyperinsulinaemia in ischaemic heart disease: the importance of myocardial infarction and left ventricular function. Q J Med (1994) 1.39
Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. QJM (1996) 1.39
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
In defence of polypharmacy. Br J Clin Pharmacol (2004) 1.38
Heart muscle disease related to HIV infection: prognostic implications. BMJ (1994) 1.37
Development of a clinical chart audit programme. Australas Radiol (2006) 1.37
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Are we drinking our neurones away? Br Med J (Clin Res Ed) (1987) 1.33
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Digitalis intoxication. Clin Sci (Lond) (1983) 1.29
Plagiarism - please don't copy. Br J Clin Pharmacol (2007) 1.29
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Biomarkers and surrogate endpoints. Br J Clin Pharmacol (2005) 1.25
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
Clinical pharmacology--providing tools and expertise for translational medicine. Br J Clin Pharmacol (2008) 1.19
Thyroid disease and the heart. Heart (2000) 1.18
Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett (1998) 1.18
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
Emergency contraception: advance provision in a young, high-risk clinic population. Obstet Gynecol (2000) 1.14
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. BMJ (1993) 1.13
ABC of monitoring drug therapy. Lithium. BMJ (1992) 1.13
An Australian Brain Bank: a critical investment with a high return! Cell Tissue Bank (2008) 1.13
Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Mol Psychiatry (2006) 1.13
What is a clinical trial? Br J Clin Pharmacol (2004) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathol (2002) 1.12
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
Drug interactions-information, education, and the British National Formulary. Br J Clin Pharmacol (2004) 1.12
Emergency contraception in Mexico City: what do health care providers and potential users know and think about it? Contraception (1999) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
A comparison of symptoms and intra-arterial ambulatory blood pressure during long term dual chamber atrioventricular synchronous (DDD) and ventricular demand (VVI) pacing. Br Heart J (1987) 1.11
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
Risk perception in drug therapy. Br J Clin Pharmacol (2006) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10